Mustafa Özdoğan, MD· @ozdogan_md · X·· 1 天前评分70
正文 · 原文
DeLLphi-305 (LBA3, #ESMO26): tarlatamab + durvalumab vs durvalumab maintenance in ES-SCLC.
Circulating figures: OS 21.1 vs 12.7 mo (HR 0.42); 12-mo OS 79.4% vs 53.3%. CRS frequent, G≥3 rare. Confirm at PS I.
@sands_jacob @ADesaiMD #LCSM #OncoAlert
52 浏览 · 1 赞 · 1 转发 · 0 回复
会议摘要
LBA3按 Presidential Symposium I 对上
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org来源：Mustafa Özdoğan, MD · x.com